Sanofi halts Phase 3 study in CIDP

Sanofi has announced that the Phase 3 MOBILIZE study of riliprubart, conducted in patients with chronic inflammatory demyelinating polyneuropathy (CIDP) refractory to standard-of-care treatment, will be discontinued. This decision, however, 'will not result in a significant financial cost' and leaves the group's 2026 financial guidance unchanged.

The decision follows an interim analysis by an independent Data Monitoring Committee, which determined that the MOBILIZE study was unlikely to demonstrate sufficient efficacy. No safety signals related to riliprubart were identified during this interim analysis.

The French healthcare giant specified that the continuation of other ongoing riliprubart trials, notably the Phase 3 VITALIZE study in CIDP patients treated with intravenous immunoglobulin (IVIg), will be evaluated accordingly.

Sanofi will work closely with investigators and site teams to ensure the closure of the MOBILIZE study, ensuring an appropriate transition of care for all enrolled patients. The company will conduct a thorough analysis of the study data to inform future research directions.